Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
暂无分享,去创建一个
G. Raghu | C. Vancheri | G Raghu | N. Crimi | M. Failla | C Vancheri | M Failla | N Crimi
[1] R. Bucala,et al. The role of circulating fibrocytes in fibrosis , 2006, Current rheumatology reports.
[2] T. Hunt,et al. Bone Marrow Contribution to Tumor-Associated Myofibroblasts and Fibroblasts , 2004, Cancer Research.
[3] K. Kuwano,et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.
[4] C. Vancheri,et al. Different Expression of TNF- α Receptors and Prostaglandin E2Production in Normal and Fibrotic Lung Fibroblasts , 2000 .
[5] F. Nicoletti,et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. , 2008, Pharmacological research.
[6] Khalid Shah,et al. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. , 2008, The Lancet. Oncology.
[7] A. Nicholson,et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. , 1999, American journal of respiratory and critical care medicine.
[8] C. Vancheri,et al. Different expression of TNF-alpha receptors and prostaglandin E(2 )Production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. , 2000, American journal of respiratory cell and molecular biology.
[9] J. Norris,et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. , 2007, American journal of respiratory and critical care medicine.
[10] K. Brown,et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. , 2006, American journal of respiratory and critical care medicine.
[11] W. MacNee,et al. Oxidative stress and regulation of glutathione in lung inflammation. , 2000, The European respiratory journal.
[12] V. Poletti,et al. Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .
[13] A. Trovato-Salinaro,et al. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis , 2006, Respiratory research.
[14] B. Willis,et al. Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.
[15] J. Stewart,et al. Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. , 2001, Respiratory medicine.
[16] J. Fujita,et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. , 1998, The European respiratory journal.
[17] N. Sharifi. Commentary: Antioxidants for cancer: new tricks for an old dog? , 2009, The oncologist.
[18] D. Lynch,et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[19] G. Raghu,et al. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. , 1989, The American review of respiratory disease.
[20] E. Kleinerman,et al. Murine bone marrow–derived mesenchymal stem cells as vehicles for interleukin‐12 gene delivery into Ewing sarcoma tumors , 2009, Cancer.
[21] S. Kudoh,et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.
[22] U. Pastorino,et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer , 2003, British Journal of Cancer.
[23] M. Andreeff,et al. Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-Based Delivery Vehicles , 2007, International journal of hematology.
[24] Carlos L. Arteaga,et al. Targeting the TGFβ signaling network in human neoplasia , 2003 .
[25] F. Spinella,et al. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. , 2008, Canadian journal of physiology and pharmacology.
[26] V. Poletti,et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis , 2006, Respiratory research.
[27] G. Oster,et al. Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.
[28] D. Sheppard,et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.
[29] M. Andreeff,et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.
[30] S. Hirohashi,et al. Increased expression of laminin‐5 and its prognostic significance in lung adenocarcinomas of small size , 2001, Cancer.
[31] M. Rojas,et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. , 2005, American journal of respiratory cell and molecular biology.
[32] A. Yoshimura,et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. , 2001, Cancer research.
[33] Mary R. Myerscough,et al. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions , 2007, Clinical & Experimental Metastasis.
[34] M. Burdick,et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. , 2007, Biochemical and biophysical research communications.
[35] J. Hagood,et al. Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. , 2007, American journal of respiratory cell and molecular biology.
[36] A. Pardo,et al. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.
[37] G. Raghu,et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.
[38] Chao Xing,et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase , 2007, Proceedings of the National Academy of Sciences.
[39] A. Georgakilas,et al. Oxidative stress, DNA methylation and carcinogenesis. , 2008, Cancer letters.
[40] G. Raghu,et al. Telomere shortening in familial and sporadic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.
[41] F. Ishikawa,et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. , 2007, The Journal of clinical investigation.
[42] R. D. du Bois,et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. , 2007, Arthritis and rheumatism.
[43] C. Vogelmeier,et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. , 1997, American journal of respiratory and critical care medicine.
[44] V. Keshamouni,et al. Activation of the Pro-survival Phosphatidylinositol 3-Kinase/AKT Pathway by Transforming Growth Factor-β1 in Mesenchymal Cells Is Mediated by p38 MAPK-dependent Induction of an Autocrine Growth Factor* , 2004, Journal of Biological Chemistry.
[45] G. Kroemer,et al. HSP27 and HSP70: Potentially Oncogenic Apoptosis Inhibitors , 2003, Cell cycle.
[46] G. Saed,et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. , 1998, Archives of dermatology.
[47] B. Alving,et al. Update in Hematology , 2001, Annals of Internal Medicine.
[48] A. Malkinson,et al. Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. , 1998, Carcinogenesis.
[49] A. Nicholson,et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. , 2002, American journal of respiratory and critical care medicine.
[50] G. Berx,et al. Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front , 2008, Histochemistry and Cell Biology.
[51] S. Mutsaers,et al. Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta isoforms on fibroblast cell cultures. , 1997, The Biochemical journal.
[52] B. Johansson,et al. Multicolor fluorescence in situ hybridization characterization of cytogenetically polyclonal hematologic malignancies. , 2005, Cancer genetics and cytogenetics.
[53] G. Nuovo,et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. , 2008, American journal of respiratory cell and molecular biology.
[54] J. Horowitz,et al. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.
[55] V. Poletti,et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. , 2003, The American journal of pathology.
[56] D. O'Gorman,et al. Beta-catenin signaling in fibroproliferative disease. , 2007, The Journal of surgical research.
[57] S. Sahn,et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.
[58] A. Nagler,et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect , 2007, Molecular Cancer Therapeutics.
[59] C. Henke,et al. β1 Integrin Regulates Fibroblast Viability during Collagen Matrix Contraction through a Phosphatidylinositol 3-Kinase/Akt/Protein Kinase B Signaling Pathway* , 2002, The Journal of Biological Chemistry.
[60] M. Jordana,et al. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. , 1988, The American review of respiratory disease.
[61] Barbara L Parsons,et al. Many different tumor types have polyclonal tumor origin: evidence and implications. , 2008, Mutation research.
[62] H. Yamasaki,et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. , 2004, Carcinogenesis.
[63] G. Hunninghake. Antioxidant therapy for idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[64] K. Chida,et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. , 2006, Chest.
[65] Johny Verschakelen,et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[66] Biao He,et al. Wnt signaling in lung cancer. , 2005, Cancer letters.
[67] M. Burdick,et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.
[68] E. White,et al. Bleomycin-Induced E Prostanoid Receptor Changes Alter Fibroblast Responses to Prostaglandin E21 , 2005, The Journal of Immunology.
[69] D. Spandidos,et al. MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis , 2002, Journal of cellular and molecular medicine.
[70] K. Surendran,et al. A role for Wnt-4 in renal fibrosis. , 2002, American journal of physiology. Renal physiology.
[71] A. Ostman,et al. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? , 2004, Lung cancer.
[72] A. Lazar,et al. Desmoid tumor: a disease opportune for molecular insights. , 2008, Histology and histopathology.
[73] R. Guo,et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.
[74] G. Raghu,et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.
[75] Michael Koval,et al. Cross-talk between pulmonary injury, oxidant stress, and gap junctional communication. , 2009, Antioxidants & redox signaling.
[76] G. Giaccone,et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Y. Atomi,et al. Coexpression of Matrilysin and Laminin-5 γ2 Chain May Contribute to Tumor Cell Migration in Colorectal Carcinomas , 2003, Digestive Diseases and Sciences.
[78] Paul Martin,et al. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration , 2006, Journal of Cell Science.
[79] G. Raghu,et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.
[80] G. Raghu,et al. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. , 1988, The American review of respiratory disease.
[81] D. O'Gorman,et al. β-Catenin Signaling in Fibroproliferative Disease , 2007 .
[82] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[83] K. Adler,et al. The myofibroblast in pulmonary fibrosis. , 1983, Chest.